Amarin Corp. plc, of London, named William Mason as its lead independent director.

AM-Pharma BV, of Bunnik, the Netherlands, appointed Jacques Arend vice president of clinical development.

Amsterdam Molecular Therapeutics, of Amsterdam, the Netherlands, appointed Philippe van Holle independent director of its supervisory board.

Anesiva Inc., of South San Francisco, named Daniel S. Janney to its board of directors.

Ariad Pharmaceuticals Inc., of Cambridge, Mass., promoted Richard W. Pascoe to chief operating officer.

Arrowhead Research Corp., of Pasadena, Calif., appointed Chad Mirkin to its board of scientific strategy.

BioMarin Pharmaceutical Inc., of Novato, Calif., appointed Gordon Vehar vice president of research.

Biomedical Corp., of San Diego, appointed Punit S. Dhillon vice president of finance and operations.

Biophan Technologies Inc., of Pittsford, N.Y., appointed Harold Gubnitsky, John Lanzafame and Travis E. Baugh to its board of directors. Lanzafame was made CEO in September.

BioReliance Corp., of Rockville, Md., named David L. Bellitt vice president of global commercial operations, biologics.

BioSeek Inc., of Burlingame, Calif., said that Roy A. Whitfield has been elected executive chairman of its board of directors. He has been on the board since November 2005.